Abstract:GG and XX are co-corresponding authors Corneal diseases are the second major cause of blindness worldwide. Corneal neovascularization (CNV) is one of the most common pathological processes in corneal diseases, leading to vision loss or even blindness in patients. However, even though different treatments for CNV are available in clinic, a safe and effective therapy remains to be an unmet medical challenge. MicroRNAs (miRNAs) play roles in regulating more than half of all protein-coding genes in mammals including those involved with angiogenesis. Therefore, modulating expression of angiogenesis-related miRNAs might be an effective approach for treating this blindness-causing corneal lesion. To this end, we first tested four angiogenesis-related miRNAs (i. e. miR-126, miR-10, miR-17a and miR-92) for their role in angiogenesis in vitro by assessing cell proliferation and tube formation of VEGF-stimulated human umbilical vein endothelial cells (HUVECs) transfected with the plasmid constructs overexpressing the pri-miRNAs or Tough Decoy (Tud) RNAs inhibitory to the corresponding target miRNAs. We found that TuD-miR-10b, pri-miR-17a and pri-miR-92 were significantly inhibitory for the cell proliferation and tube formation of HUVECs, while TuD-miR-126-5p could impede HUVEC tube formation but not proliferation. Our data reveal that miR-126 and miR-10 are pro-angiogenic regulators, whereas miR-17a and miR-92 are negative regulators of angiogenesis, suggesting the feasibility of using miRNA as therapeutic targets to modulate angiogenesis in CNV. We next set out to identify more target miRNAs that play roles in CNV. To date, there has been no report on miRNA expression profile of CNV. Using Nanostring technologies and the classic alkali-burn induced CNV mouse model, we profiled small RNAs prepared from the corneal tissues harvested from the study mice before and days 5, 10 and 15 after alkali injury for expression levels of 618 mouse miRNAs. We found 35 up-regulated and 3 down-regulated miRNAs in the mouse neovascularized corneas. Currently, we are in the process of confirming expression profiles of those candidate target miRNAs by qRT-PCR. For proof-of-concept, we proposed to use rAAV vector for efficient delivery of those pri-miRNAs or their corresponding Tud RNAs to the corneas of alkali-burn induced CNV mice and evaluate their potency in preventing or treating CNV. To this end, we first assessed several serotypes of rAAV EGFP for gene transfer efficiency in mouse corneas after delivery by ectopic eye drops, or intrastromal or subconjunctival injections to identify the most efficient AAV serotype and method of delivery for miRNA therapeutics. The results of those experiments will be presented. In sum, our study has great clinical relevance; miRNA-targeted novel therapeutics that can be delivered as either rAAV or synthetic nucleic acid drugs (i. e. miRNA mimics and antagomir) might offer an additional clinical option for treating CNV.

Genome Editing VEGFA Prevents Corneal Neovascularization in Vivo

Safety and efficacy of CRISPR-mediated genome ablation of VEGFA as a treatment for choroidal neovascularization in nonhuman primate eyes

CRISPR/Cas9 mediated specific ablation of vegfa in retinal pigment epithelium efficiently regresses choroidal neovascularization

Reduced Expression of VEGF-A in Human Retinal Pigment Epithelial Cells and Human Muller Cells Following CRISPR-Cas9 Ribonucleoprotein-Mediated Gene Disruption

A siRNA targeting vascular endothelial growth factor-A inhibiting experimental corneal neovascularization.

Nme2 Cas9-mediated therapeutic editing in inhibiting angiogenesis after wet age-related macular degeneration onset

CRISPR-dcas9 Optogenetic Nanosystem for the Blue Light-Mediated Treatment of Neovascular Lesions

[Small Interference RNA Targeting Vascular Endothelial Growth Factor Inhibits Rat Corneal Neovascularization].

A Synergistic Therapy with Antioxidant and Anti‐VEGF: Towards Its Safe and Effective Elimination for Corneal Neovascularization

Multi-gene Targeted Antiangiogenic Therapies for Experimental Corneal Neovascularization

[Antisense Vascular Endothelial Growth Factor Suppressed Corneal Neovascularization in Rats].

586. Development of Anti-Angiogenic Mirna Therapeutics for Corneal Neovascularization

Inhibition of experimental choroidal neovascularization in mice by anti-VEGFA/VEGFR2 or non-specific siRNA

AAV-mediated in vivo genome editing in vascular endothelial cells.

Safeguarding genome integrity during gene-editing therapy in a mouse model of age-related macular degeneration

Lentiviral delivery of co-packaged Cas9 mRNA and a Vegfa-targeting guide RNA prevents wet age-related macular degeneration in mice

A Synergistic Therapy with Antioxidant and Anti-VEGF: Toward Its Safe and Effective Elimination for Corneal Neovascularization

cRGD-modified hybrid lipopolymeric nanoplexes for gene editing in the posterior segment of the eye

CasRx-mediated RNA targeting prevents choroidal neovascularization in a mouse model of age-related macular degeneration

Gene Therapy Intervention in Neovascular Eye Disease: A Recent Update

Tissue-targeted and localized AAV5-DCN and AAV5-PEDF combination gene therapy abrogates corneal fibrosis and concurrent neovascularization in rabbit eyes in vivo